Shire Eating Disorder Drug Gets F.D.A. Priority

Will this pill help those with binge eating disorders and bulemia?

by Ben Hirschle

Shire’s  hyperactivity drug Vyvanse will get a priority review in the United States as a potential treatment for binge eating disorder, showing a willingness by U.S. regulators to consider novel ways to fight eating problems.

The U.S. Food and Drug Administration last week approved Orexigen Therapeutics’s long-awaited obesity pill Contrave and an advisory panel also backed Novo Nordisk’s injectable drug liraglutide for weight loss.

Dublin-based Shire, which is being acquired by U.S. drugmaker AbbVie, said on Monday that the FDA was expected to give its decision on the new use of Vyvanse by February 2015.

Vyvanse is currently only approved for Attention-Deficit Hyperactivity Disorder.

This post may include affiliate links.


The SkinnyMs. team believes that all people, regardless of age, size, and fitness level, have the power to transform their lives — they just need the resources to do so. The SkinnyMs. method promotes healthy living through a combination of clean eating and regular exercise. We offer everything you need to be successful.

More by Skinny

Leave a Reply

Your email address will not be published. Required fields are marked *